Moreover, investigations by Tsai et al. reinforced the association between GLP-1 agonists and specific gut microbial alterations and explained their role in promoting anti-inflammatory and anti-obesity effects through modulation of the gut microbiota [39]. The gene discussed is GCG; the disease is Obesity.